First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2012-04-19 01:06:53Open Document File Size: 570,63 KBShare Result on FacebookCityPrinceton / Philadelphia / El Segundo / Atlanta / /CompanyLG / Endoscopy-America Inc. / Karl Storz Endoscopy-America Inc. / /ContinentEurope / /CountryUnited States / /EventFDA Phase / /FacilityThomas Jefferson University / /IndustryTermtreatment of non-muscle invasive bladder cancer / treatment of superficial bladder cancer / care for bladder cancer / treatment of nonmuscle invasive bladder cancer / /MedicalConditionsmall papillary tumors / scar / anaphylactic shock / inadequately treated tumor / higher tumor / bladder tumours / gross hematuria / bladder cancer / recurrent bladder tumor / transitional carcinoma / Carcinoma / T1 bladder cancer / newly diagnosed bladder cancer / nonmuscle invasive bladder cancer / hypersensitivity / porphyria / residual tumor / tumor / superficial urothelial carcinomas / Cancer / tumors / cystitis / hematuria / Herr H. Tumor / tumour / bladder spasm / erythema / fulgurated and papillary tumors / inflammatory lesions / non-muscle-invasive urothelial carcinoma / visible tumor / superficial bladder tumors / bladder tumors / inflammation / non-muscle invasive bladder cancer / superficial bladder cancer / /MedicalTreatmentBCG therapy / catheter / catheters / bypass / /OrganizationKimmel Cancer Center / Department of Urology / Thomas Jefferson University / Philadelphia / FDA / American Cancer Society / European Association of Urology / Pharmacy committee / /PersonJ. Ryan Mark / HAL-FC / Karl Storz / Edouard J. Trabulsi / Francisco Gelpi-Hammerschmidt / Leonard G. Gomella / /PositionPDD camera head / Grossman HB / surgeon / /ProductCysview / mitomycin / Cysview solution / /ProvinceOrStateAlabama / Pennsylvania / California / /PublishedMediumThe Canadian Journal / /SocialTag |